Explore the Agenda

8:30 am Morning Coffee & Registration

9:25 am Chairs Opening Remarks

Characterizing mRNA Therapeutics to Define Integrity, Structure, & Analytical Reliability

9:30 am Roundtable Discussion: Translating Complex mRNA Characterization Assays into QC-Ready Strategies to Reduce Downtime between Teams

Senior Director - Analytical Development & Quality Control, Arcturus Therapeutics
Director, Analytical Development, Tessera Therapeutics
  • How to adapt AD assays into validated QC workflows to ensure reproducibility across sites and manufacturing scales
  • How to overcome challenges of assay transfer, variability, and lack of reference standards to safeguard consistency and compliance
  • How to embed standardized characterization workflows to support smoother regulatory submissions, tech transfer and global comparability

10:30 am From Bench to Bioinformatics: Harnessing RNA Sequencing as a Next-Generation Analytical Tool for mRNA Characterization & Q

Postdoctoral Research Fellow, Massachusetts College of Pharmacy and Health Sciences

 Applying RNA-Seq to detect impurities, truncated transcripts, and dsRNA species that escape traditional assays

  • Comparing sequencing against conventional integrity and potency assays to define regulatory-ready standards
  • Establishing seamless workflows from sample prep to bioinformatics to bride wet lab and digital pipelines and accelerate decision-making
  • Positioning sequencing-based analytics as a potential platform method for comparability, release, and long-term stability studies

11:00 am Morning Break & Speed Networking

Our dedicated speed networking session is the perfect opportunity to have in-depth conversations  and forge long-lasting connections with fellow technical experts working within mRNA Analytical  Development & Quality Control.

Defining mRNA Functionality Through Assays that Accurately Reflect Biological Activity & Predict Clinical Performance

12:00 pm Next Generation RNA Medicines: STARR® Self-Amplifying mRNA Vaccines

Senior Director - Analytical Development & Quality Control, Arcturus Therapeutics
  • Differences between Arcturus sa-mRNA and approved mRNA vaccines
  • EMA Approval Case Studies:
    • Characterization of mRNA
    • Fragments in Drug Substance
    • Efficacy/tolerability of mRNA Fragments In Vivo
    • Lipid Mass Balance
    • Future Perspectives

12:30 pm Decoding RNA Quality with Sequencing-Based Analytics

Head of Scientific Platforms & Strategy, Eclipse Bioinnovations
  •  Compare manufacturing conditions using sequencing-based quality control
  • Identify dsRNA impurities that drive off-target immune and safety risks
  • Reveal potency-relevant insights from drug product uptake to translation

1:00 pm Establishing Core Endpoints That Truly Correlate with Biological Readouts to Validate mRNA Functionality

QC Specialist & Data Analyst, Genetech Biotech
  • Comparing in vitro, cell-based and engineered model systems to determine which assays should be standardized to best represent functional mRNA performance
  • Differentiating between integrity, encapsulation, and total mRNA content to determine which attributes meaningfully correlate with biological activity
  • Lessons learnt from CQAs that failed to predict immunogenicity or efficacy to streamline submission packages that prove mRNA functionality

1:30 pm Rapid and precise characterisation of RNA and ligands in LNPs via scatter-free absorbance

CEO, Marama Labs
  • Learn how scatter-free absorbance enables quantification of RNA and ligand concentration without dyes, surfactants or disruption of particles
  • Understand how spectral deconvolution of UV spectra can simultaneously quantify payloads and ligands
  • See how this new technique is being used to streamline RNA therapy development by massively simplifying RNA and antibody assays

1:40 pm Lunch Break

Toxicity & Impurity Characterization in mRNA Therapeutics to Identify, Quantify & Remove Immunogenic Byproducts

2:40 pm Advancing the toolset for mRNA/LNP characterization/platform method development

Principal Mass Spectrometry (MS) Applications Specialist, Waters Corp
  • New nucleases for more efficient MS-based sequencing of mRNA
  • New wide pore SEC columns for QC of mRNA/LNP modalities
  • New MS and compliance-ready informatics tools for mRNA sequencing/characterization

3:10 pm Advancing Impurity and Residual Analysis to Strengthen mRNA Product Quality & QC Readiness

Director, Analytical Development, Tessera Therapeutics
  • Developing and optimizing assays to detect and quantify critical impurities and residuals including dsRNA, proteins, and DNA in mRNA therapeutics
  • Translating analytical rigor from development to QC to ensure reproducibility, compliance, and regulatory acceptance

3:40 pm Chairs Closing Remarks

3:45 pm Drinks Reception & Poster Session

Contribute to the conversation and share your cutting-edge research with like-minded AD & QC Experts. To present a poster, register your place and submit an abstract highlighting your breakthroughs. *Please visit the website for T&Cs for presenting a poster